Responses
PostScript
Correspondence
A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options
Compose a Response to This Article
Other responses
No responses have been published for this article.